
Amgen's Oncology Pipeline: Investigating Next-Generation Medicines



SCAN TO DOWNLOAD



Oncology pipeline mura



Clinical trials

This information reflects public disclosures as of Oct 26, 2023. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. The descriptions herein contain forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise

ALL = Acute lymphoblastic leukemia; AML = Acute myeloid leukemia; BiTE* = Bispecific T-cell engager; CAR = Chimeric antigen receptor; CIT = Chemotherapy-induced thrombocytopenia; CRC = Colorectal cancer; G/GEJC = Gastric or gastroesophageal junction cancer; G/GEJC = Gastroesophageal junct NEPC = Neuroendocrine prostate cancer; NSCLC = Non-small cell lung cancer; PNH = Paroxysmal nocturnal hemoglobinuria; SCLC = Small cell lung cancer

* The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification. XmAb[®] is a registered trademark of Xencor

© 2023 Amgen Inc. All rights reserved. USA-OCF-82325

OTHER SOLID TUMORS				C HEMATOLOGY		
or CIT	Target: IL-21			Target: CD19		
		Latikafusp Bi-functional fusion protein		*	Blinatumomab	
Phase 3	Ť	Various solid tumors Phase 1			ALL Phase 3	
	Target PRMT5			Target: Proteasome		
	- Alex	AMG 193 Small molecule		-29m	Carfilzomib Small molecule	
Phase 3		Various solid tumors Phase 1			Multiple myeloma Phase 3	
	Target: CLDN6				Pediatric ALL Phase 2	
nab	* ~	AMG 794		Target: Complement C5		
Phase 2	\$*	BiTE* molecule Ovarian cancer and various solid tumors Phase 1		8 .09	ABP 959* Monoclonal antibody	
				783	PNH Phase 3	
				Target: MCL-1		
Phase 2				AB	AMG 176 Small molecule	
					AML/MDS Phase 1	

